News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Coronado Biosciences Receives Orphan-Drug Designation From FDA for CNDO-109-Activated Allogeneic Natural Killer Cells for the Treatment of AML


6/19/2012 9:32:49 AM

BURLINGTON, Mass., June 19, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to CNDO-109-Activated Allogeneic Natural Killer Cells (CNDO-109) for "the treatment of acute myeloid leukemia (AML)."

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES